Should gatifloxacin be included in the model list of essential medicines?
Eur Respir J
.
2018 Feb 7;51(2):1702329.
doi: 10.1183/13993003.02329-2017.
Print 2018 Feb.
Authors
Chen-Yuan Chiang
1
2
3
,
Arnaud Trébucq
4
,
Alberto Piubello
4
5
,
Hans L Rieder
6
7
,
Armand Van Deun
4
8
Affiliations
1
International Union Against Tuberculosis and Lung Disease, Paris, France
[email protected]
.
2
Division of Pulmonary Medicine, Dept of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
3
Division of Pulmonary Medicine, Dept of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
4
International Union Against Tuberculosis and Lung Disease, Paris, France.
5
Damien Foundation, Niamey, Niger.
6
Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.
7
Tuberculosis Consultant Services, Kirchlindach, Switzerland.
8
Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
PMID:
29437946
DOI:
10.1183/13993003.02329-2017
No abstract available
Publication types
Letter
Comment
MeSH terms
Drugs, Essential*
Gatifloxacin*
Humans
Tuberculosis, Multidrug-Resistant
World Health Organization
Substances
Drugs, Essential
Gatifloxacin